Clinical Trial Update: Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis [NA]

View source ↗

Summary

Clinical trial update on BD followed by autologous stem cell transplant and maintenance BD for initial treatment of Monoclonal Immunoglobulin Deposition Disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis
• Light Chain Deposition Disease
• Monoclonal Immunoglobulin Deposition Disease

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) | NA | Status: COMPLETED | Results posted: 2020-03-30